<p><strong>Cello World Limited</strong> (NSE:CELLO) 正面临一个艰难的时期，因其一周前发布的第三季度业绩令人失望，这可能会显著影响市场对该股票的看法。结果显示，收入为 ₹55 亿，低于分析师预期的 6.3%。法定每股收益 (EPS) 为 ₹2.88，严重低于预期，约低了 22%。对于投资者来说，这是一个重要的时刻，因为他们可以在报告中跟踪公司的表现，查看专家对明年的预测，并观察业务预期是否有所变化。考虑到这一点，我们收集了最新的法定预测，以了解分析师对明年的预期。</p>
<p>人工智能即将改变医疗保健。这 20 只股票正在从早期诊断到药物发现等各个方面进行工作。最棒的是——它们的市值都在 100 亿美元以下——现在仍然有机会提前布局。</p>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/417994730-earnings-and-revenue-growth-1-dark-2/1771380188595?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="1642" height="1048" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/417994730-earnings-and-revenue-growth-1-dark-2/1771380188595"/></p>
<p>NSEI:CELLO 收益和收入增长 2026 年 2 月 18 日</p>
<p>考虑到最新的业绩，Cello World 七位分析师的共识预测是 2027 年收入为 ₹258 亿。这反映出与过去 12 个月相比，收入有显著的 11% 增长。法定每股收益预计将上涨 23%，达到 ₹17.33。在这份收益报告之前，分析师们预测 2027 年的收入为 ₹279 亿，每股收益 (EPS) 为 ₹19.51。近期业绩后，分析师们似乎不那么乐观，降低了他们的收入预测，并大幅下调了每股收益的预期。</p>
<p>查看我们对 Cello World 的最新分析</p>
<p>共识价格目标下降了 16%，降至 ₹587，疲软的收益前景显然导致了估值预期的下滑。共识价格目标只是各个分析师目标的平均值，因此——查看基础估计的范围可能会很有帮助。目前，最乐观的分析师将 Cello World 的每股价值定为 ₹640，而最悲观的则定为 ₹515。尽管如此，考虑到估计值相对接近，分析师们对他们的估值相当有信心，这表明 Cello World 是一个容易预测的业务，或者分析师们都在使用相似的假设。</p>
<p>获取这些预测的更多背景的一种方法是查看它们与过去表现的比较，以及同一行业其他公司的表现。我们要强调的是，Cello World 的收入增长预计将放缓，预计到 2027 年底的年化增长率为 8.9%，远低于过去五年的历史年均增长率 13%。相比之下，该行业其他有分析师覆盖的公司预计年收入增长为 14%。考虑到预计的增长放缓，显然 Cello World 的增长也预计将低于其他行业参与者。</p>
<h2>结论</h2>
<p>最大的担忧是分析师下调了每股收益的预期，这表明 Cello World 可能面临业务逆风。不幸的是，他们也下调了收入预期，我们的数据表明其表现低于更广泛的行业。尽管如此，每股收益对企业的内在价值更为重要。此外，分析师们还下调了他们的价格目标，这表明最新消息导致了对企业内在价值的更大悲观情绪。</p>
<p>话虽如此，公司的长期收益轨迹远比明年的表现更为重要。我们有来自多位 Cello World 分析师的预测，直到 2028 年，你可以在我们的平台上免费查看。</p>
<p>另一个需要考虑的因素是管理层和董事最近是否有买入或卖出股票。我们在平台上提供了过去十二个月所有公开市场股票交易的概述。</p>
<h3><strong>新：AI 股票筛选器和警报</strong></h3>
<p>我们的新 AI 股票筛选器每天扫描市场以发现机会。</p>
<p>• 分红强劲的股票（收益率 3%+）</p>
<p>• 具有内部买入的被低估小盘股</p>
<p>• 高增长的科技和 AI 公司</p>
<p>或者从 50 多个指标中构建自己的筛选器。</p>
<p>立即免费探索</p>

<p>Cello World Limited (NSE:CELLO) 公布了令人失望的第三季度业绩，收入为 55 亿印度卢比，比预期低 6.3%，每股收益为 2.88 印度卢比，比预测低 22%。分析师已将 2027 年的收入预测下调至 258 亿印度卢比（增长 11%），每股收益下调至 17.33 印度卢比（增长 23%）。共识目标价下降 16% 至 587 印度卢比，反映出盈利前景的降低。Cello World 预期的增长率为 8.9%，低于行业平均水平的 14%。尽管长期盈利预测延续至 2028 年，分析师对潜在的商业逆风和内在价值表示担忧</p>

<p>It's shaping up to be a tough period for <strong>Cello World Limited</strong> (NSE:CELLO), which a week ago released some disappointing third-quarter results that could have a notable impact on how the market views the stock. Results showed a clear earnings miss, with ₹5.5b revenue coming in 6.3% lower than what the analystsexpected. Statutory earnings per share (EPS) of ₹2.88 missed the mark badly, arriving some 22% below what was expected. This is an important time for investors, as they can track a company's performance in its report, look at what experts are forecasting for next year, and see if there has been any change to expectations for the business. With this in mind, we've gathered the latest statutory forecasts to see what the analysts are expecting for next year.</p>
<div class="lb-trans"><p><strong>Cello World Limited</strong> (NSE:CELLO) 正面临一个艰难的时期，因其一周前发布的第三季度业绩令人失望，这可能会显著影响市场对该股票的看法。结果显示，收入为 ₹55 亿，低于分析师预期的 6.3%。法定每股收益 (EPS) 为 ₹2.88，严重低于预期，约低了 22%。对于投资者来说，这是一个重要的时刻，因为他们可以在报告中跟踪公司的表现，查看专家对明年的预测，并观察业务预期是否有所变化。考虑到这一点，我们收集了最新的法定预测，以了解分析师对明年的预期。</p>
</div><p>AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early.</p>
<div class="lb-trans"><p>人工智能即将改变医疗保健。这 20 只股票正在从早期诊断到药物发现等各个方面进行工作。最棒的是——它们的市值都在 100 亿美元以下——现在仍然有机会提前布局。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/417994730-earnings-and-revenue-growth-1-dark-2/1771380188595" alt="" original-src="https://images.simplywall.st/asset/chart/417994730-earnings-and-revenue-growth-1-dark-2/1771380188595"/></p>
<p>NSEI:CELLO Earnings and Revenue Growth February 18th 2026</p>
<div class="lb-trans"><p>NSEI:CELLO 收益和收入增长 2026 年 2 月 18 日</p>
</div><p>Taking into account the latest results, the consensus forecast from Cello World's seven analysts is for revenues of ₹25.8b in 2027. This reflects a meaningful 11% improvement in revenue compared to the last 12 months. Statutory earnings per share are predicted to shoot up 23% to ₹17.33. Before this earnings report, the analysts had been forecasting revenues of ₹27.9b and earnings per share (EPS) of ₹19.51 in 2027. The analysts seem less optimistic after the recent results, reducing their revenue forecasts and making a substantial drop in earnings per share numbers.</p>
<div class="lb-trans"><p>考虑到最新的业绩，Cello World 七位分析师的共识预测是 2027 年收入为 ₹258 亿。这反映出与过去 12 个月相比，收入有显著的 11% 增长。法定每股收益预计将上涨 23%，达到 ₹17.33。在这份收益报告之前，分析师们预测 2027 年的收入为 ₹279 亿，每股收益 (EPS) 为 ₹19.51。近期业绩后，分析师们似乎不那么乐观，降低了他们的收入预测，并大幅下调了每股收益的预期。</p>
</div><p>See our latest analysis for Cello World</p>
<div class="lb-trans"><p>查看我们对 Cello World 的最新分析</p>
</div><p>The consensus price target fell 16% to ₹587, with the weaker earnings outlook clearly leading valuation estimates. The consensus price target is just an average of individual analyst targets, so - it could be handy to see how wide the range of underlying estimates is. Currently, the most bullish analyst values Cello World at ₹640 per share, while the most bearish prices it at ₹515. Even so, with a relatively close grouping of estimates, it looks like the analysts are quite confident in their valuations, suggesting Cello World is an easy business to forecast or the the analysts are all using similar assumptions.</p>
<div class="lb-trans"><p>共识价格目标下降了 16%，降至 ₹587，疲软的收益前景显然导致了估值预期的下滑。共识价格目标只是各个分析师目标的平均值，因此——查看基础估计的范围可能会很有帮助。目前，最乐观的分析师将 Cello World 的每股价值定为 ₹640，而最悲观的则定为 ₹515。尽管如此，考虑到估计值相对接近，分析师们对他们的估值相当有信心，这表明 Cello World 是一个容易预测的业务，或者分析师们都在使用相似的假设。</p>
</div><p>One way to get more context on these forecasts is to look at how they compare to both past performance, and how other companies in the same industry are performing. We would highlight that Cello World's revenue growth is expected to slow, with the forecast 8.9% annualised growth rate until the end of 2027 being well below the historical 13% p.a. growth over the last five years. By way of comparison, the other companies in this industry with analyst coverage are forecast to grow their revenue at 14% per year. Factoring in the forecast slowdown in growth, it seems obvious that Cello World is also expected to grow slower than other industry participants.</p>
<div class="lb-trans"><p>获取这些预测的更多背景的一种方法是查看它们与过去表现的比较，以及同一行业其他公司的表现。我们要强调的是，Cello World 的收入增长预计将放缓，预计到 2027 年底的年化增长率为 8.9%，远低于过去五年的历史年均增长率 13%。相比之下，该行业其他有分析师覆盖的公司预计年收入增长为 14%。考虑到预计的增长放缓，显然 Cello World 的增长也预计将低于其他行业参与者。</p>
</div><h2>The Bottom Line</h2>
<div class="lb-trans"><h2>结论</h2>
</div><p>The biggest concern is that the analysts reduced their earnings per share estimates, suggesting business headwinds could lay ahead for Cello World. Unfortunately, they also downgraded their revenue estimates, and our data indicates underperformance compared to the wider industry. Even so, earnings per share are more important to the intrinsic value of the business. Furthermore, the analysts also cut their price targets, suggesting that the latest news has led to greater pessimism about the intrinsic value of the business.</p>
<div class="lb-trans"><p>最大的担忧是分析师下调了每股收益的预期，这表明 Cello World 可能面临业务逆风。不幸的是，他们也下调了收入预期，我们的数据表明其表现低于更广泛的行业。尽管如此，每股收益对企业的内在价值更为重要。此外，分析师们还下调了他们的价格目标，这表明最新消息导致了对企业内在价值的更大悲观情绪。</p>
</div><p>With that said, the long-term trajectory of the company's earnings is a lot more important than next year. We have estimates - from multiple Cello World analysts - going out to 2028, and you can see them free on our platform here.</p>
<div class="lb-trans"><p>话虽如此，公司的长期收益轨迹远比明年的表现更为重要。我们有来自多位 Cello World 分析师的预测，直到 2028 年，你可以在我们的平台上免费查看。</p>
</div><p>Another thing to consider is whether management and directors have been buying or selling stock recently. We provide an overview of all open market stock trades for the last twelve months on our platform, here.</p>
<div class="lb-trans"><p>另一个需要考虑的因素是管理层和董事最近是否有买入或卖出股票。我们在平台上提供了过去十二个月所有公开市场股票交易的概述。</p>
</div><h3><strong>New:</strong> AI Stock Screener &amp; Alerts</h3>
<div class="lb-trans"><h3><strong>新：AI 股票筛选器和警报</strong></h3>
</div><p>Our new AI Stock Screener scans the market every day to uncover opportunities.</p>
<div class="lb-trans"><p>我们的新 AI 股票筛选器每天扫描市场以发现机会。</p>
</div><p>• Dividend Powerhouses (3%+ Yield)</p>
<div class="lb-trans"><p>• 分红强劲的股票（收益率 3%+）</p>
</div><p>• Undervalued Small Caps with Insider Buying</p>
<div class="lb-trans"><p>• 具有内部买入的被低估小盘股</p>
</div><p>• High growth Tech and AI Companies</p>
<div class="lb-trans"><p>• 高增长的科技和 AI 公司</p>
</div><p>Or build your own from over 50 metrics.</p>
<div class="lb-trans"><p>或者从 50 多个指标中构建自己的筛选器。</p>
</div><p>Explore Now for Free</p>
<div class="lb-trans"><p>立即免费探索</p>
</div>

Cello World Limited 刚刚未能达到盈利预期，但分析师们已经更新了他们的模型